EyePoint Pharmaceuticals, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
6.15
-0.20 (-3.15%)
Feb 21, 2025, 4:00 PM EST - Market closed
EyePoint Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for EyePoint Pharmaceuticals stock have an average target of 25.71, with a low estimate of 15 and a high estimate of 33. The average target predicts an increase of 318.05% from the current stock price of 6.15.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for EyePoint Pharmaceuticals stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Buy | 3 | 4 | 4 | 4 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $33 | Strong Buy | Maintains | $33 | +436.59% | Feb 6, 2025 |
| Citigroup | Citigroup | Strong Buy Initiates $33 | Strong Buy | Initiates | $33 | +436.59% | Jan 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +257.72% | Dec 5, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $22 | Strong Buy | Maintains | $30 → $22 | +257.72% | Nov 11, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $28 → $33 | Strong Buy | Maintains | $28 → $33 | +436.59% | Nov 8, 2024 |
Financial Forecast
Revenue This Year
44.06M
from 46.02M
Decreased by -4.26%
Revenue Next Year
18.45M
from 44.06M
Decreased by -58.13%
EPS This Year
-2.30
from -1.82
EPS Next Year
-2.64
from -2.30
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 59.9M | 52.7M | 48.9M | |||
| Avg | 44.1M | 18.4M | 8.8M | |||
| Low | 31.1M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 30.1% | 19.5% | 165.2% | |||
| Avg | -4.3% | -58.1% | -52.1% | |||
| Low | -32.5% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.91 | -1.81 | -2.14 | |||
| Avg | -2.30 | -2.64 | -2.96 | |||
| Low | -2.89 | -3.71 | -3.38 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.